<html><head><link rel="stylesheet" type="text/css" href="css/style.css"></head><body><div id="main"><h1>Scignal</h1></div> <div class="container"><div class="row"><div class="search"><h2>All Results for : "chimeric antigen receptor" OR "CAR" OR "CAR-"</a></h2></div><table><tr><td class="head"><h3>BioRxiv</h3></td><td class="head"><h3>PubMed</h3></td></tr><tr><div class="row"><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: convertibleCARs: A chimeric antigen receptor system for flexible control of activity and antigen targeting</h4><p><a href="https://www.biorxiv.org/content/10.1101/696401v2">Link</a></p><p><b>Date:</b> 2019-07-09</p><p><b>Authors:</b> Kyle E. Landgraf ... Kaman Chan Kim</p><p><b>Downloads:</b> 692</p><p><b>Relevance Score:</b> 0.71</p></div><div class="everything-else-tail"><p><b>Abstract:</b> We have developed a chimeric antigen receptor (CAR) platform that functions as a modular system to address limitations of current CAR therapies.  An inert form of the NKG2D extracellular domain (iNKG2D) was used as the ectodomain of the CAR to generate convertibleCAR-T cells.</p></div></td></div><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE).</h4><p><a href="https://ncbi.nlm.nih.gov/pubmed/31753925">Link</a></p><p><b>Date:</b> 2019-11-22</p><p><b>Authors:</b> Ibrahim Yakoub-Agha ...  Nicolaus Kröger</p><p><b>Journal:</b> Haematologica</p><p><b>IF (7 or above):</b> 7.53</p><p><b>Relevance Score:</b> 0.57</p></div><div class="everything-else-tail"><p><b>Abstract:</b> Chimeric antigen receptor (CAR) T cells are a novel class of anti-cancer therapy in which autologous or allogeneic T cells are engineered to express a CAR targeting a membrane antigen.  In Europe, tisagenlecleucel (Kymriah™) is approved for the treatment of refractory/relapsed acute lymphoblastic le ....</p></div></td></div></tr><tr><div class="row"><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Impaired tumor death receptor signaling drives resistance to CAR T cell therapy</h4><p><a href="https://www.biorxiv.org/content/10.1101/627562v1">Link</a></p><p><b>Date:</b> 2019-05-05</p><p><b>Authors:</b> Nathan Singh ... Marco Ruella</p><p><b>Downloads:</b> 1231</p><p><b>Relevance Score:</b> 0.57</p></div><div class="everything-else-tail"><p><b>Abstract:</b> Cellular immunotherapy using T cells engineered to express chimeric antigen receptors targeting CD19 (CART19) leads to long-term remission in patients with B-cell malignancies.  Unfortunately, a significant fraction of patients demonstrate primary resistance to CART19 or experience relapse after achieving remission.</p></div></td></div><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Retrospective analysis of the efficacy of cytokine-induced killer cell immunotherapy combined with first-line chemotherapy in patients with metastatic colorectal cancer.</h4><p><a href="https://ncbi.nlm.nih.gov/pubmed/32076550">Link</a></p><p><b>Date:</b> 2020-02-22</p><p><b>Authors:</b> Qiu-Zhong Pan ...  Jian-Chuan Xia</p><p><b>Journal:</b> Clin Transl Immunology</p><p><b>IF (7 or above):</b> 8.18</p><p><b>Relevance Score:</b> 0.14</p></div><div class="everything-else-tail"><p><b>Abstract:</b> Objectives: Fluoropyrimidine-based chemotherapy regimens are the current first-line treatment for metastatic colorectal cancer (mCRC); however, the outcome is often unsatisfactory.  The present study aimed to determine the effect of combined cytokine-induced killer (CIK) cell immunotherapy and first ....</p></div></td></div></tr><tr><div class="row"><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Functional effects of chimeric antigen receptor co-receptor signaling domains in human Tregs</h4><p><a href="https://www.biorxiv.org/content/10.1101/749721v1">Link</a></p><p><b>Date:</b> 2019-08-29</p><p><b>Authors:</b> Nicholas A.J. Dawson ... Megan K Levings</p><p><b>Downloads:</b> 752</p><p><b>Relevance Score:</b> 0.57</p></div><div class="everything-else-tail"><p><b>Abstract:</b> Antigen-specific regulatory T cells (Tregs) engineered with chimeric antigen receptor (CARs) are a potent immunosuppressive cellular therapy in multiple disease models.  To date the majority of CAR Treg studies employed second generation CARs, encoding a CD28 or 4-1BB co-receptor signaling domain and CD3zeta, but it was not known if this CAR design was optimal for Tregs.</p></div></td></div><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Awake functional MRI detects neural circuit dysfunction in a mouse model of autism.</h4><p><a href="https://ncbi.nlm.nih.gov/pubmed/32076634">Link</a></p><p><b>Date:</b> 2020-02-22</p><p><b>Authors:</b> Tomokazu Tsurugizawa ...  Toru Takumi</p><p><b>Journal:</b> Sci Adv</p><p><b>IF (7 or above):</b> 12.53</p><p><b>Relevance Score:</b> 0.14</p></div><div class="everything-else-tail"><p><b>Abstract:</b> MRI has potential as a translational approach from rodents to humans.  However, given that mouse functional MRI (fMRI) uses anesthetics for suppression of motion, it has been difficult to directly compare the result of fMRI in "unconsciousness" disease model mice with that in "consciousness" patient ....</p></div></td></div></tr><tr><div class="row"><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Three-Compartment Model of CAR T-cell Immunotherapy</h4><p><a href="https://www.biorxiv.org/content/10.1101/779793v1">Link</a></p><p><b>Date:</b> 2019-09-24</p><p><b>Authors:</b> Brendon de Jesus Rodrigues ... Regina C. Almeida</p><p><b>Downloads:</b> 322</p><p><b>Relevance Score:</b> 0.57</p></div><div class="everything-else-tail"><p><b>Abstract:</b> Immunotherapy has gained great momentum with CAR T (chimeric antigen receptor) cellular therapy, in which the patients T lymphocytes are genetically manipulated to recognize tumor-specific antigens to increase elimination efficiency.  Although recently approved by FDA to treat B cell malignancies, issues such as dose, administration protocol, toxicity, resistance to immunotherapy, among others, remain open and are the subject of intense research nowadays.</p></div></td></div><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Current advances and outlooks in immunotherapy for pancreatic ductal adenocarcinoma.</h4><p><a href="https://ncbi.nlm.nih.gov/pubmed/32061257">Link</a></p><p><b>Date:</b> 2020-02-17</p><p><b>Authors:</b> Jia-Qiao Fan ...  Jianxun Song</p><p><b>Journal:</b> Mol. Cancer</p><p><b>IF (7 or above):</b> 11.35</p><p><b>Relevance Score:</b> 0.14</p></div><div class="everything-else-tail"><p><b>Abstract:</b> Pancreatic ductal adenocarcinoma (PDAC) is an incurable cancer resistant to traditional treatments, although a limited number of early-stage patients can undergo radical resection.  Immunotherapies for the treatment of haematological malignancies as well as solid tumours have been substantially impr ....</p></div></td></div></tr><tr><div class="row"><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Overcoming Immunological Resistance Enhances the Efficacy of a Novel anti-tMUC1 CAR T Cell Treatment Against Pancreatic Ductal Adenocarcinoma</h4><p><a href="https://www.biorxiv.org/content/10.1101/642934v1">Link</a></p><p><b>Date:</b> 2019-05-20</p><p><b>Authors:</b> Mahboubeh Yazdanifar ... Pinku Mukherjee</p><p><b>Downloads:</b> 311</p><p><b>Relevance Score:</b> 0.57</p></div><div class="everything-else-tail"><p><b>Abstract:</b> Chimeric antigen receptor engineered T cells (CAR T cells) have shown remarkable success in treating hematologic cancers.  However, this efficacy has yet to translate to treatment in solid tumors.</p></div></td></div><td></td></tr><tr><div class="row"><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Post-translational covalent assembly of CAR and synNotch receptors for programmable antigen targeting</h4><p><a href="https://www.biorxiv.org/content/10.1101/2020.01.17.909895v1">Link</a></p><p><b>Date:</b> 2020-01-17</p><p><b>Authors:</b> Jason Lohmueller ... Olivera J. Finn</p><p><b>Downloads:</b> 283</p><p><b>Relevance Score:</b> 0.57</p></div><div class="everything-else-tail"><p><b>Abstract:</b> Chimeric antigen receptors (CARs) and synthetic Notch (synNotch) receptors are engineered cell-surface receptors that sense a target antigen and respond by activating T cell receptor signaling or a customized gene program, respectively.  To expand the targeting capabilities of these receptors, we have developed switchable adaptor receptor systems for which receptor specificity can be directed post-translationally via covalent attachment of a co-administered antibody.</p></div></td></div><td></td></tr><tr><div class="row"><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Chlorotoxin Redirects Chimeric Antigen Receptor T Cells for Specific and Effective Targeting of Glioblastoma</h4><p><a href="https://www.biorxiv.org/content/10.1101/2020.01.24.918888v1">Link</a></p><p><b>Date:</b> 2020-01-25</p><p><b>Authors:</b> Dongrui Wang ... Christine E. Brown</p><p><b>Downloads:</b> 137</p><p><b>Relevance Score:</b> 0.57</p></div><div class="everything-else-tail"><p><b>Abstract:</b> While chimeric antigen receptor (CAR) T cells have demonstrated antitumor activity against glioblastoma (GBM), tumor heterogeneity remains a critical challenge.  To more effectively target heterogeneous GBMs, we report the development of a novel peptide-based CAR exploiting the GBM-binding potential of chlorotoxin (CLTX).</p></div></td></div><td></td></tr><tr><div class="row"><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Tumor control via targeting PD-L1 with chimeric antigen receptor modified NK cells</h4><p><a href="https://www.biorxiv.org/content/10.1101/2020.01.30.926535v1">Link</a></p><p><b>Date:</b> 2020-01-30</p><p><b>Authors:</b> Yvette Robbins ... Clint T. Allen</p><p><b>Downloads:</b> 126</p><p><b>Relevance Score:</b> 0.57</p></div><div class="everything-else-tail"><p><b>Abstract:</b> Failed T cell-based immunotherapies in the presence of genomic alterations in antigen presentations pathways may be overcome by NK cell-based immunotherapy.  This approach may still be limited by the presence of immunosuppressive myeloid populations.</p></div></td></div><td></td></tr><tr><div class="row"><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Feasibility of real-time in vivo 89Zr-DFO-labeled CAR T-cell trafficking using PET imaging</h4><p><a href="https://www.biorxiv.org/content/10.1101/789727v1">Link</a></p><p><b>Date:</b> 2019-10-01</p><p><b>Authors:</b> Suk Hyun Lee ... Jin-Sook Ryu</p><p><b>Downloads:</b> 102</p><p><b>Relevance Score:</b> 0.57</p></div><div class="everything-else-tail"><p><b>Abstract:</b> Introduction: Chimeric antigen receptor (CAR) T-cells have been developed recently, producing impressive outcomes in patients with hematologic malignancies.  However, there is no standardized method for cell trafficking and in vivo CAR T-cell monitoring.</p></div></td></div><td></td></tr><tr><div class="row"><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Functionalized microcarriers improve T cell manufacturing by facilitating migratory memory T cell production and increasing CD4/CD8 ratio</h4><p><a href="https://www.biorxiv.org/content/10.1101/646760v1">Link</a></p><p><b>Date:</b> 2019-05-23</p><p><b>Authors:</b> Nathan J. Dwarshuis ... Krishnendu Roy</p><p><b>Downloads:</b> 608</p><p><b>Relevance Score:</b> 0.43</p></div><div class="everything-else-tail"><p><b>Abstract:</b> Adoptive cell therapies (ACT) using chimeric antigen receptor (CAR) T cells have shown promise in treating cancer, but manufacturing large numbers of high quality cells remains challenging.  Critically, current T cell expansion technologies only partially recapitulate the in vivo microenvironment found in the human lymph nodes.</p></div></td></div><td></td></tr><tr><div class="row"><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Perfect adaptation of CD8+ T cell responses to constant antigen input over a wide range of affinity is overcome by costimulation</h4><p><a href="https://www.biorxiv.org/content/10.1101/535385v2">Link</a></p><p><b>Date:</b> 2019-01-30</p><p><b>Authors:</b> Nicola Trendel ... Omer Dushek</p><p><b>Downloads:</b> 676</p><p><b>Relevance Score:</b> 0.29</p></div><div class="everything-else-tail"><p><b>Abstract:</b> Maintaining and limiting T cell responses to constant antigen stimulation is critical to control pathogens and maintain self-tolerance, respectively.  Antigen recognition by T cell receptors (TCRs) induces signalling that activates T cells to produce cytokines and also leads to the downregulation of surface TCRs.</p></div></td></div><td></td></tr><tr><div class="row"><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Highly efficient site-directed gene insertion in primary human natural killer cells using homologous recombination and CRISPaint delivered by AAV</h4><p><a href="https://www.biorxiv.org/content/10.1101/743377v1">Link</a></p><p><b>Date:</b> 2019-08-22</p><p><b>Authors:</b> Meisam Naeimi Kararoudi ... Dean A. Lee</p><p><b>Downloads:</b> 483</p><p><b>Relevance Score:</b> 0.29</p></div><div class="everything-else-tail"><p><b>Abstract:</b> Human peripheral blood natural killer (NK) cells have strong antitumor activity and have been used successfully in several clinical trials.  Modifying NK cells with a chimeric antigen receptor (CAR) can improve their targeting and increase specificity.</p></div></td></div><td></td></tr><tr><div class="row"><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Identification of human CD4+ T cell populations with distinct antitumor activity</h4><p><a href="https://www.biorxiv.org/content/10.1101/2019.12.31.891317v1">Link</a></p><p><b>Date:</b> 2020-01-02</p><p><b>Authors:</b> Michelle H. Nelson ... Chrystal Paulos</p><p><b>Downloads:</b> 396</p><p><b>Relevance Score:</b> 0.29</p></div><div class="everything-else-tail"><p><b>Abstract:</b> How naturally arising human CD4+ T helper subsets impact tumor immunity is unknown.  We reported that human CD4+CD26high T cells elicit potent immunity against solid tumor malignancies.</p></div></td></div><td></td></tr></table></div><hr></div></body></html>